FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease
FDA approves Ryoncil, the first MSC therapy to treat steroid-refractory acute graft-versus-host disease (SR-a GVHD) in pediatric patients 2 months of age and ol